The Future of Erectile Dysfunction Therapy II: Novel Pharmacotherapy and Innovative Technology

Le, Brian; Burnett, Arthur L.

doi:10.1007/978-1-4939-3100-2_12

Cited by 5 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a number of novel PDE5 and other molecules under development may hold promise for the treatment of ED,2, 47 in the medium term, new formulations designed to overcome some of the limitations of existing treatments by offering improved discretion and flexibility are likely to contribute most effectively to reducing the above-mentioned stigma that is often still associated with ED, and encourage acceptance of and continuation with therapy.…”

Section: Pharmacological Approaches To Meeting Unmet Needsmentioning

confidence: 99%

“…Novel approaches for the treatment of ED are currently being investigated, including stem cell therapy, molecules targeting alternative vasoactive pathways, trophic factors, gene therapy, and new technologies such as penile vibratory stimulation, external penile support devices, internal pudendal artery stenting, extracorporeal low-intensity shockwave therapy, endovascular revascularization, and tissue engineering. However, PDE5 remains the most understood molecular target in the effective pharmacological management of ED 1, 2, 47. Accordingly, innovative dosage formulations of PDE5-Is are being developed that are designed to optimize efficacy, safety and patient acceptability, convenience, and compliance.…”

Section: Overview Of Latest Developments In Pde5-ismentioning

confidence: 99%

“…A range of treatment options, both non-invasive and invasive, is available for the management of erectile dysfunction (ED). Treatment approaches include psychosexological strategies, intraurethral or intracavernosal alprostadil self-injections, vacuum-assisted erection devices, low-intensity extracorporeal shock wave treatment, and penile implants 1, 2, 3. However, oral pharmacological management with phosphodiesterase 5 inhibitors (PDE5-Is) remains the first-line treatment choice for ED because of the excellent efficacy and safety profile of PDE5-Is 1, 3, 4…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil

Jannini

Droupy

2018

Sexual Medicine

View full text Add to dashboard Cite

Introduction Phosphodiesterase type 5 inhibitors (PDE5-Is) have an excellent efficacy and tolerability profile and remain the first-line choice for the treatment of erectile dysfunction (ED). However, ED is still an underdiagnosed and undertreated condition, and many men prematurely discontinue therapy with conventional dosage formulations despite successful intercourse. Aim To review the unmet needs and expectations of patients with ED and describe the latest pharmaceutical innovations in the field of PDE5-I formulations designed to address these needs, with particular reference to a new orodispersible film (ODF) formulation of the PDE5-I, sildenafil. Methods Online literature search in PubMed and the Cochrane Library. Main Outcome Measure To identify English-language publications relevant to the aims of the present review. Results Improved recognition and management of ED would enable the early diagnosis of underlying and comorbid conditions that contribute to ED, leading to improved patient health and health-related quality of life. To ensure successful outcomes and patient and partner satisfaction, the complex and personal issues that influence the patient’s needs and expectations regarding treatment for ED must be considered along with their personal experiences and preferences. Innovative drug delivery systems, including orally disintegrating formulations, have been developed as alternatives to conventional dosage forms with the aim of improving patient convenience and acceptability and enhancing compliance. These alternative formulations include the sildenafil ODF, which is designed to improve acceptance and compliance over conventional solid dosage forms and extend the treatment options for men with ED by offering a convenient and discrete dosage form of a drug with proven efficacy. Conclusion The sildenafil ODF is an example of an innovative dosage formulation for ED that can be used interchangeably with the conventional film-coated formulation to better address the needs and expectations of men with ED. Jannini EA, Droupy S. Needs and Expectations of Patients with Erectile Dysfunction: An Update on Pharmacological Innovations in Phosphodiesterase Type 5 Inhibition with Focus on Sildenafil. Sex Med 2019;7:1–10.

show abstract

Section: Pharmacological Approaches To Meeting Unmet Needsmentioning

confidence: 99%